Oxford, U.K.-based medical technology company Optellum has received the CE Mark for its Virtual Nodule Clinic, an artificial intelligence (AI) application for early lung cancer diagnosis based on CT scans.
Virtual Nodule Clinic is an AI-powered clinical decision-support software tool designed to help clinicians identify and track at-risk patients who present suspicious lung nodules that may or may not be cancerous.
The software integrates the clinically validated lung cancer prediction score based on AI analysis of imaging studies and has the potential to improve clinical care coordination and decisions, according to the company.
This is the latest milestone for Optellum's Virtual Nodule Clinic, which was cleared by the U.S. Food and Drug Administration in early 2021 and is among the first AI-assisted diagnosis applications for lung cancer, the company said.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
